These glucose level-dependent mechanisms of incretins suggest that DPP-4 inhibitors can improve glycemic control and reduce glucose fluctuations in patients with type 2 diabetes mellitus compared with other insulin secretagogues [22]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.